Epitalon FDA Status: An Insomnia Vote, With No Efficacy Data

Current status: Epitalon is not FDA-approved, is not on the 503A bulk drug substances list, and no US pharmacy may legally compound it today. On July 24, 2026 an FDA advisory committee recommended adding it — for insomnia, and while the agency's own reviewers were telling the room there was no published efficacy data to evaluate.

The vote

Epitalon was heard on day two of the July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting. The committee recommended it for the section 503A bulks list by 7–5 in favor with one abstention¹.

One honesty note on that number: outlets differ. Regulatory trade press reported 7–5 with an abstention; at least one national outlet reported the tally as 7–4. FDA has not published minutes, so treat the precise count as provisional and the direction — narrowly favorable — as the reliable part. We would rather flag the disagreement than launder it into a clean-looking figure.

The indication FDA actually reviewed: insomnia

FDA published the use it evaluated for each substance in advance. For Epitalon free base and Epitalon acetate, that use was insomnia².

That single word does a lot of work here, because Epitalon is not sold as a sleep aid. It is sold as a longevity and anti-aging peptide — telomerase activation, telomere length, pineal function, "biological age." None of that was evaluated. Longevity, telomere biology, healthspan, anti-aging and athletic recovery were not on the agenda and were not voted on, for Epitalon or for any other substance at the meeting.

So the situation is unusually stark: the substance received a favorable recommendation for an indication almost nobody buys it for, and its actual marketing claims were never examined by anyone in the room.

The part that should stop you: no published efficacy data

Across all seven substances, FDA's scientific reviewers recommended against listing and described an absence of reliable human data³. For Epitalon specifically, trade coverage of the meeting reports that FDA's position was that there was no published efficacy data for insomnia, alongside immunogenicity concerns and potential peptide impurities¹.

That is worth stating plainly, because it is the whole story of this vote: a majority of the committee recommended a substance for a compounding list, for an indication with no published efficacy data behind it.

The committee that produced that majority had been expanded weeks earlier with eight new members, most with ties to the peptide industry, including physicians running clinics and companies that sell peptide protocols⁴⁵. NPR characterized the panel's endorsement as "a striking rejection of the FDA's stance"³.

What still has to happen

A favorable PCAC vote lists nothing. To add Epitalon to 21 CFR 216.23, FDA must publish a proposed rule, take public comment, and issue a final rule⁶. That list currently contains six substances — Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide, five of them topical-only — and no peptide⁶.

The only completed 503A bulks rulemaking took roughly three years, from a proposed rule in December 2016 to a final rule effective March 21, 2019⁷. FDA has published no timeline for this round. The "proposed rule in 9 to 18 months" claim now circulating traces to vendor and affiliate blogs, not to any agency document.

What you should not conclude

• •Not that Epitalon is FDA approved or endorsed. It is neither, and it cannot become so through this pathway. 21 CFR 216.23(d) states that representing a compounded drug made with a listed bulk substance as "FDA approved, or otherwise endorsed by FDA generally or for a particular indication" causes it to be misbranded under sections 502(a) and/or 502(bb) of the Act⁶ — a rule that applies after listing, not just before.
• •Not that FDA validated any longevity claim. It reviewed insomnia. There is no FDA finding here about telomeres, biological age, or lifespan, and there is no anti-aging endpoint anywhere in the meeting record.
• •Not that a favorable vote implies evidence. For Epitalon it demonstrably did not — the agency's position was that published efficacy data for the reviewed indication was absent.
• •Not that anything changed for tested athletes. Epitalon has no marketing authorization for human therapeutic use by any government health authority, which is the trigger for WADA's S0 class — non-approved substances, prohibited at all times. See the WADA 2026 prohibited list for peptides.

Where Epitalon sits on FDA's lists today

Epitalon is not in FDA's live Category 2 table. It appears in the second table on that page — substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators"⁸. A withdrawn nomination is a procedural event, not a safety clearance, and it does not make Epitalon compoundable by anyone.

Meanwhile the substance actually reviewed for the sleep indication most people associate with this space — emideltide, or DSIP — was the one substance of the seven the committee rejected, 6–7 with one abstention, after being evaluated for opioid withdrawal, chronic insomnia and narcolepsy¹². We cover that molecule in DSIP: the delta sleep-inducing peptide, reviewed.

The bottom line

Epitalon received a narrow favorable recommendation for insomnia — an indication FDA reviewers said had no published efficacy data — from a committee whose composition had been changed weeks earlier. Longevity, the reason Epitalon is actually bought, was never reviewed. Nothing is listed, nothing is approved, and no rule has been proposed.

For the full meeting, read what actually happened at the FDA peptide advisory vote. For the legal picture across the whole category, see are peptides legal?. And for how to evaluate any peptide vendor's claims in the meantime, see peptide vendor red flags and scams.